National Cancer Institute (NCI): all 3,554 studies

Page 27 of 36. Open to participants first (334), then studies with results posted, then the rest; newest registration first within each.

• Phase I Study of Intravenous Triapine (IND # 68338) in Combination With Pelvic Radiation Therapy With or Without Weekly Intravenous Cisplatin Chemotherapy for Locally Advanced Cervical, Vaginal, or Pelvic Gynecologic MalignanciesCompletedNCT00335998Phase 1
• Belinostat and Isotretinoin in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by SurgeryCompletedNCT00334789Phase 1
• Vorinostat and Doxorubicin in Treating Patients With Metastatic or Locally Advanced Solid TumorsCompletedNCT00331955Phase 1
• Ixabepilone in Treating Young Patients With Refractory Solid TumorsCompletedNCT00331643Phase 2
• Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic SyndromesCompletedNCT00331513Phase 1
• AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS TumorsCompletedNCT00326664Phase 1
• Vorinostat and Alvocidib in Treating Patients With Advanced Solid TumorsCompletedNCT00324480Phase 1
• CDDO to Treat Solid Tumors and LymphomasCompletedNCT00322140Phase 1
• AZD2171 in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic LeukemiaCompletedNCT00321724Phase 2
• AZD2171 to Treat Children and Adolescents With Solid Tumors or Acute Myelogenous LeukemiaCompletedNCT00321581Phase 1
• Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib MesylateCompletedNCT00316953Phase 1
• Temsirolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma MultiformeCompletedNCT00316849Phase 1
• Natural History and Biology of Skin Neurofibromas in Neurofibromatosis Type 1CompletedNCT00314119
• AZD2171 and Combination Chemotherapy in Treating Women With Locally Advanced Breast CancerCompletedNCT00310089Not applicable
• Vorinostat and Bortezomib in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00310024Phase 1
• Bortezomib and Gemcitabine in Treating Patients With Recurrent or Metastatic Nasopharyngeal CancerCompletedNCT00305734Phase 2
• AZD2171 in Treating Patients With Recurrent Glioblastoma MultiformeCompletedNCT00305656Phase 2
• Mechanism of Action of High-Dose IL-2 (Aldesleukin) in Metastatic Melanoma and Kidney CancerCompletedNCT00304460Phase 1
• Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic MelanomaTerminatedNCT00303836Phase 2
• Sorafenib and Bortezomib in Treating Patients With Advanced CancerCompletedNCT00303797Phase 1
• 7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic SyndromesCompletedNCT00301938Phase 1
• Sorafenib in Treating Patients With Kidney Cancer That Has Spread to the BrainCompletedNCT00301847Phase 2
• Rituximab and Oblimersen in Treating Patients With Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's LymphomaTerminatedNCT00301795Phase 2
• SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Phase Chronic Myelogenous Leukemia, or Chronic Lymphocytic LeukemiaTerminatedNCT00301769Phase 1
• Cellular Adoptive Immunotherapy in Treating a Patient Who Has Undergone a Donor Stem Cell Transplant for Breast Cancer That Has Spread to the LungCompletedNCT00301730Phase 1
• Nicotine Skin Patch in Treating Patients With Kaposi's SarcomaCompletedNCT00295984Phase 2
• 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or LymphomaCompletedNCT00293345Phase 1
• Natural History Study of Moles and Suspicious MelanomaCompletedNCT00288938
• 3-AP and Radiation Therapy in Treating Patients With Stage III Pancreatic Cancer That Cannot Be Removed By SurgeryCompletedNCT00288093Phase 1
• Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic MelanomaCompletedNCT00288041Phase 2
• Vorinostat, Paclitaxel, and Carboplatin in Treating Patients With Advanced or Refractory Solid TumorsCompletedNCT00287937Phase 1
• Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Healthy MenCompletedNCT00287833Phase 1
• BAY 43-9006 (Sorafenib) to Treat Patients With Kaposi's SarcomaTerminatedNCT00287495Phase 1
• Combination Chemotherapy in Treating Young Patients With Advanced Solid TumorsCompletedNCT00281944Phase 1
• Sorafenib in Treating Patients With Recurrent Non-Hodgkin's LymphomaCompletedNCT00278382Phase 2
• Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory AnemiaCompletedNCT00278330Phase 1
• Radiation Therapy in Treating Patients With Cervical CancerCompletedNCT00278304Phase 2
• Temsirolimus in Treating Patients With Metastatic Solid Tumor or Lymphoma That Cannot Be Removed By Surgery Who Have Different Levels of Liver FunctionCompletedNCT00275093Phase 1
• Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous LeukemiaCompletedNCT00275080Phase 1
• ZD6474 to Treat Advanced Brain Cancer in PatientsCompletedNCT00272350Phase 1
• Vorinostat and Temozolomide in Treating Patients With Malignant GliomasActive, not recruitingNCT00268385Phase 1
• Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By SurgeryCompletedNCT00255762Phase 2
• Sorafenib and Temsirolimus in Treating Patients With Unresectable or Metastatic Solid TumorsCompletedNCT00255658Phase 1
• Sorafenib in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00253578Phase 2
• Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic CancerWithdrawnNCT00253526Phase 2
• Smokefree.Gov Website in Helping United States Federal Employees Quit SmokingCompletedNCT00245076Not applicable
• Sulindac in Preventing Breast Cancer in Women at High Risk for Breast CancerCompletedNCT00245024Phase 1
• Tipifarnib and Sorafenib Tosylate in Treating Patients With Biopsiable Advanced CancerCompletedNCT00244972Phase 1
• Vorinostat and Gemcitabine in Treating Patients With Metastatic or Unresectable Solid TumorsCompletedNCT00243100Phase 1
• Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple MyelomaTerminatedNCT00243035Phase 1/2
• Cediranib Maleate in Treating Patients With Locally Advanced or Metastatic Liver CancerCompletedNCT00238394Phase 2
• S0514 Sorafenib in Treating Patients With Unresectable or Metastatic Gallbladder Cancer or CholangiocarcinomaCompletedNCT00238212Phase 2
• Defined Green Tea Catechin Extract in Preventing Esophageal Cancer in Patients With Barrett's EsophagusCompletedNCT00233935Phase 1
• Vorinostat and Bortezomib in Treating Patients With Metastatic or Unresectable Solid TumorsCompletedNCT00227513Phase 1
• Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous LeukemiaCompletedNCT00217646Phase 1
• Azacitidine and Recombinant Interferon Alfa-2b in Treating Patients With Stage III or Stage IV Melanoma or Stage IV Kidney Cancer That Cannot Be Removed By SurgeryCompletedNCT00217542Phase 1
• Bortezomib and Antiviral Therapy Followed By Effusion Drainage, Bevacizumab, and Combination Chemotherapy in Treating Patients With Primary Effusion LymphomaCompletedNCT00217503Phase 2
• Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or LeukemiaCompletedNCT00217412Phase 1
• Vaccine Therapy, GM-CSF, and Interferon Alfa-2b in Treating Patients With Locally Advanced or Metastatic Cancer That Expresses Carcinoembryonic Antigen (CEA)CompletedNCT00217373Phase 1
• Ixabepilone in Treating Patients With Metastatic, Recurrent, or Unresectable Kidney CancerCompletedNCT00182702Phase 2
• Suberoylanilide Hydroxamic Acid, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Progressive Metastatic or Unresectable Colorectal Cancer or Other Solid TumorsCompletedNCT00138177Phase 1
• Sorafenib, Cetuximab, and Irinotecan in Treating Patients With Advanced or Metastatic Colorectal CancerCompletedNCT00134069Phase 1
• Vorinostat in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cavity CancerCompletedNCT00132067Phase 2
• Sorafenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous LeukemiaCompletedNCT00131989Phase 1
• Effect of Lifestyle Factors and Hormone Function on Breast Density in Healthy Hispanic Women Who Are Undergoing Mammography for Breast Cancer ScreeningCompletedNCT00131950Not applicable
• Trastuzumab in Treating Patients With Metastatic or Recurrent Salivary Gland CancerTerminatedNCT00126607Phase 2
• Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity CancerCompletedNCT00126542Phase 2
• Arsenic Trioxide and Pamidronate in Treating Patients With Advanced Solid Tumors or Multiple MyelomaCompletedNCT00124605Phase 1
• SJG-136 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By SurgeryCompletedNCT00121290Phase 1
• 17-AAG and Sorafenib in Treating Patients With Unresectable or Metastatic Solid TumorsCompletedNCT00121264Phase 1
• Sorafenib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By SurgeryCompletedNCT00119249Phase 2
• 17-AAG and Irinotecan in Treating Patients With Locally Advanced or Metastatic Solid TumorsCompletedNCT00119236Phase 1
• Cisplatin, Irinotecan, and Bevacizumab, in Treating Patients With Small Cell Lung CancerCompletedNCT00118235Phase 2
• Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung CancerCompletedNCT00118183Phase 2
• Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney FunctionCompletedNCT00118170Phase 1
• A Pilot Trial of Oral Topotecan for the Treatment of Refractory Advanced Solid Neoplasms Expressing HIF-1aCompletedNCT00117013Phase 1
• Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck CancerCompletedNCT00114283Phase 2
• Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative DisordersCompletedNCT00114257Phase 1
• Capecitabine, Bevacizumab, and Radiation Therapy Followed By Gemcitabine and Bevacizumab in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By SurgeryCompletedNCT00114179Phase 2
• Vaccine and Antibody Treatment of Prostate CancerCompletedNCT00113984Phase 1
• Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT00112853Phase 1
• Alvocidib in Treating Patients With Locally Advanced or Metastatic Solid TumorsTerminatedNCT00112684Phase 1
• Temsirolimus and Bryostatin 1 in Treating Patients With Unresectable or Metastatic Solid TumorsCompletedNCT00112476Phase 1
• Study of Disease Severity in Adults With Neurofibromatosis Type 1 (NF1)CompletedNCT00111384
• Central Nervous System Disease in HIV-infected Children on HAARTCompletedNCT00110331
• Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Newly Diagnosed Brain TumorsTerminatedNCT00110032Phase 1
• Decitabine With or Without Valproic Acid in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT00109824Phase 1
• Vaccine Therapy in Treating Patients With Recurrent Prostate CancerCompletedNCT00109811Phase 2
• Enzastaurin to Treat Recurrent Brain TumorTerminatedNCT00108056Phase 1
• EF5 in Finding Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Cervical, Endometrial, or Ovarian Epithelial CancerCompletedNCT00107445Phase 2
• Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma.CompletedNCT00107432Phase 2
• GW572016 to Treat Recurrent Malignant Brain TumorsCompletedNCT00107003Phase 2
• Lenalidomide in Treating Young Patients With Relapsed or Refractory Solid Tumors or Myelodysplastic SyndromesCompletedNCT00104962Phase 1
• Cilengitide in Treating Patients With Metastatic Prostate CancerCompletedNCT00103337Phase 2
• S0413 Lapatinib in Treating Patients With Locally Advanced or Metastatic Stomach CancerCompletedNCT00103324Phase 2
• Isolated Hepatic Perfusion With Melphalan Followed by Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal CancerCompletedNCT00103298Phase 2
• 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic CancerTerminatedNCT00103272Phase 1
• SJG-136 in Treating Patients With Advanced Solid TumorsCompletedNCT00103220Phase 1
• Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung CancerCompletedNCT00101348Phase 1/2
• Tipifarnib in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT00101296Phase 1

← National Cancer Institute (NCI) overview and focus areas